Compare TPVG & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | MIST |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2M | 176.3M |
| IPO Year | 2013 | 2019 |
| Metric | TPVG | MIST |
|---|---|---|
| Price | $5.23 | $1.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $5.90 | ★ $8.00 |
| AVG Volume (30 Days) | 430.7K | ★ 2.9M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 17.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.67 | $2,915.14 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.48 | $1.00 |
| 52 Week High | $7.53 | $3.06 |
| Indicator | TPVG | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 54.55 |
| Support Level | $5.03 | $1.89 |
| Resistance Level | $5.39 | $2.30 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 38.31 | 46.97 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).